Kopfbereich

Esate čia:

AOP naujienų skyrius


Spaudos skyrius

Čia pateikiama bendroji informacija apie AOP Orphan. Mūsų darbuotojas mielai atsakys į Jūsų klausimus ar komentarus:

Modestas Jocius
AOP Orphan Pharmaceuticals AG atstovybė Baltijos šalims
Didžioji g. 25
LT-01128 Vilnius
Lietuva
Tel.: +370 672 12222
Faksas: +370 5 2755203
El. paštas: modestas.jocius(at)aoporphan.com

AOP Orphan´s submission for marketing authorization of Ropeginterferon alfa-2b for treatment of Polycythemia Vera (PV) in the European Union (EU) has resumed after clock-stop. The conclusion of this centralized procedure is...

AOP Orphan Pharmaceuticals AG, the Austrian specialist for rare diseases, will implement ‘Mobile IntelligenceTM (MI)’ - the smart CRM Tool from leading Life-Sciences consultant, IQVIA.

Bioprojet Pharma SAS and AOP Orphan Pharmaceuticals AG (AOP Orphan) entered a distribution agreement for Wakix®The covered territory includes mainly Central and Northern European countriesWakix® is approved for treatment of...

AOP Orphan supports the Christian Doppler Laboratory for Iron Metabolism and Anemia Research at the Medical University of Innsbruck, Austria, opening on January 31st, 2018. To read the full press release in German, please click...

High rates and durable Clinical and Hematological response were achieved with Ropeginterferon alfa-2b at 24 months of treatment The disease modifying capability of Ropeginterferon alfa-2b was further supported by 24 month...

Bendrovė AOP Orphan Pharmaceuticals AG šiandien pranešė, kad įsigijo Selisistat, labai selektyvų SIRT1 inhibitorių. Anksčiau atliktuose eksperimentiniuose tyrimuose pademonstruota, kad preparatas sergant daugeliu...

An interview with Dr Rudolf Widmann, CEO and Dr Christoph Klade, CSO about the current status of Vienna, Austria as a Research & Development base, its specifics, hurdles and chances,  which was published recently in...

AOP Orphan Pharmaceuticals AG (AOP Orphan) today announced that RAPIBLOC® (Rapibloc, 300 mg powder for solution for infusion) will as of June 19th be first commercialized by its distribution partner Amomed Pharma GmbH (Amomed)...

Interviu su  generaliniu direktoriumi, daktaru Rudolf Widmann ir vyriausiuoju moksliniu vadovu, daktaru Christoph Klade apie „Orphan“ veiklą tvarių inovacijų srityje sergančių retomis ligomis pacientų labui  ir...

Highlights: Ultra-short acting and highly cardio-selective beta blocker Rapibloc® (Landiolol) receives regulatory approval in Europe.Rapibloc® (Landiolol) allows rapid control of heart rate with a straightforward dosing scheme...

As an easy-to-use and highly reliable inhalation powder, the antipsychotic ADASUVE® has revolutionized the treatment of agitation in patients suffering from schizophrenia or bipolar disorder. This was also confirmed by experts...

The Austrian pharmaceutical company AOP Orphan, which specialises in rare diseases and innovative therapies, will in future market the antiarrhythmic drug BRINAVESS®, developed by Cardiome Pharma Corp., Canada, in Central Europe....

The Austrian pharmaceutical company AOP Orphan is a European pioneer in the field of rare diseases. Industry expert Hans Peter Hasler (58) joined AOP Orphan’s Supervisory Board at the beginning of the year. The Swiss native...

AOP Orphan and Ferrer Internacional are expanding their long-standing partnership to include the marketing of the anti-psychotic drug Adasuve® (Staccato® Loxapine) in Central and Eastern Europe.